{
    "clinical_study": {
        "@rank": "65659", 
        "brief_summary": {
            "textblock": "To evaluate the safety and efficacy of foscarnet induction therapy for treatment of AIDS\n      patients experiencing their first episode of cytomegalovirus (CMV) retinitis. To evaluate\n      the safety and efficacy of three different foscarnet maintenance therapy regimens. To\n      determine the pharmacokinetics of intermittent administration of foscarnet with or without\n      concomitant administration of zidovudine (AZT)."
        }, 
        "brief_title": "An Open Study of Foscarnet Treatment First Episode CMV-Retinitis in AIDS Patients", 
        "condition": [
            "Cytomegalovirus Retinitis", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Retinitis", 
                "Cytomegalovirus Retinitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following are excluded:\n\n          -  Any clinically significant pulmonary or neurologic impairment (e.g., patients who are\n             intubated or comatose).\n\n          -  Corneal, lens, or vitreous opacification which precludes examination of the fundi, or\n             evidence of tuberculotic, diabetic and/or hypertensive retinopathy.\n\n          -  Known allergy to foscarnet.\n\n          -  Recurrent episode of cytomegalovirus (CMV) retinitis.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Nephrotoxic drugs.\n\n        Patients with the following are excluded:\n\n          -  Recurrent episode of cytomegalovirus (CMV) retinitis.\n\n          -  Any clinically significant pulmonary or neurologic impairment (e.g., patients who are\n             intubated or comatose).\n\n          -  Corneal, lens, or vitreous opacification which precludes examination of the fundi, or\n             evidence of tuberculotic, diabetic, and/or hypertensive retinopathy.\n\n          -  Known allergy to foscarnet.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Ganciclovir for cytomegalovirus (CMV) retinitis.\n\n          -  Foscarnet for CMV retinitis.\n\n        Patients with AIDS as defined by the CDC with manifest first episode cytomegalovirus (CMV)\n        retinitis, as identified by its characteristic ophthalmoscopic appearance and verified by\n        fundus photography.\n\n          -  Patients must be able to give informed consent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002039", 
            "org_study_id": "020A", 
            "secondary_id": "88-FOS-01"
        }, 
        "intervention": {
            "intervention_name": "Foscarnet sodium", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Foscarnet", 
                "Phosphonoacetic Acid"
            ]
        }, 
        "keyword": [
            "Retinitis", 
            "AIDS-Related Opportunistic Infections", 
            "Drug Therapy, Combination", 
            "Foscarnet", 
            "Cytomegalovirus Infections", 
            "Acquired Immunodeficiency Syndrome", 
            "Antiviral Agents", 
            "Zidovudine"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77004"
                }, 
                "name": "Foscarnet Research Program / Park Plaza Hosp"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "An Open Study of Foscarnet Treatment First Episode CMV-Retinitis in AIDS Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "reference": {
            "citation": "Ussery FM, Karol C, Conklin R, Gathe J, Stool E, Redding K. Preliminary results from an on-going prospective evaluation of foscarnet in the treatment of AIDS-associated cytomegalovirus retinitis. Int Conf AIDS. 1989 Jun 4-9;5:551 (abstract no MCP60)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002039"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astra USA", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 1991"
    }, 
    "geocoordinates": {
        "Foscarnet Research Program / Park Plaza Hosp": "29.76 -95.369"
    }
}